PathoQuest is preparing clinical trials of its next-generation sequencing-based infectious disease diagnostic assay, which it hopes to launch in Europe in early 2015 and later in the US, initially for use in immunocompromised patients.

The Paris-based company, a spinout of the Pasteur Institute and the Ecole Nationale Vétérinaire d'Alfort, ENVA, recently raised €3.8 million ($5 million) in a Series B private equity funding round that it will use to finance the trials as well as to develop its technology further.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.